{
  "id": 3982133,
  "title": "#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy",
  "url": "https://urgent.news/2026/08/28/esc26-crispr-therapeutics-to-pursue-highest-dose-of-its-lipid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-28T14:30:23.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/esc26-crispr-therapeutics-to-pursue-highest-dose-of-its-lipid-lowering-gene-editing-therapy/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to early-stage data presented Friday at the annual meeting of the European Society of Cardiology. The company will ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}